HTML Microdata document

This HTML5 document contains 85 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n20	http://linked.opendata.cz/resource/drugbank/drug/DB01253/identifier/pubchem-compound/
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n21	http://linked.opendata.cz/resource/drugbank/drug/DB01253/identifier/pubchem-substance/
n7	http://linked.opendata.cz/resource/AHFS/
n12	http://linked.opendata.cz/resource/drugbank/company/
foaf	http://xmlns.com/foaf/0.1/
n11	http://linked.opendata.cz/resource/mesh/concept/
n24	http://linked.opendata.cz/resource/drugbank/drug/DB01253/identifier/drugbank/
n18	http://bio2rdf.org/drugbank:
adms	http://www.w3.org/ns/adms#
n16	http://linked.opendata.cz/resource/drugbank/drug/DB01253/identifier/chemspider/
n25	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n15	http://linked.opendata.cz/resource/drugbank/drug/DB01253/identifier/chebi/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n19	http://linked.opendata.cz/resource/drugbank/medicinal-product/
n10	http://linked.opendata.cz/ontology/mesh/
owl	http://www.w3.org/2002/07/owl#
n3	http://linked.opendata.cz/ontology/drugbank/
n14	http://www.drugs.com/cdi/
n9	http://linked.opendata.cz/resource/drugbank/drug/DB01253/identifier/wikipedia/
n4	http://linked.opendata.cz/resource/drugbank/property/
n23	http://linked.opendata.cz/resource/drugbank/drug/DB01253/identifier/pharmgkb/
xsdh	http://www.w3.org/2001/XMLSchema#
n22	http://linked.opendata.cz/resource/drugbank/drug/DB01253/identifier/kegg-compound/
n6	http://linked.opendata.cz/resource/atc/
n5	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB01253
rdf:type: n3:Drug
n3:description: An ergot alkaloid with uterine and vascular smooth muscle contractile properties. [PubChem]
n3:group: approved
n3:halfLife: t<sub>1/2 α</sub>=10 minutes; t<sub>1/2 β</sub>=2 hours
n3:indication: Used to treat postpartum haemorrhage and postabortion haemorrhage in patients with uterine atony.
owl:sameAs: n18:DB01253 n25:DB01253
dcterms:title: Ergonovine
adms:identifier: n9:Ergonovine n15:4822 n16:391970 n20:443884 n21:46506922 n22:C07543 n23:PA449487 n24:DB01253
n3:mechanismOfAction: Ergonovine directly stimulates the uterine muscle to increase force and frequency of contractions. With usual doses, these contractions precede periods of relaxation; with larger doses, basal uterine tone is elevated and these relaxation periods will be decreased. Contraction of the uterine wall around bleeding vessels at the placental site produces hemostasis. Ergonovine also induces cervical contractions. The sensitivity of the uterus to the oxytocic effect is much greater toward the end of pregnancy. The oxytocic actions of ergonovine are greater than its vascular effects. Ergonovine, like other ergot alkaloids, produces arterial vasoconstriction by stimulation of alpha-adrenergic and serotonin receptors and inhibition of endothelial-derived relaxation factor release. It is a less potent vasoconstrictor than ergotamine. As a diagnostic aid (coronary vasospasm), ergonovine causes vasoconstriction of coronary arteries.
n3:packager: n12:271B5F6F-363D-11E5-9242-09173F13E4C5 n12:271B5F70-363D-11E5-9242-09173F13E4C5 n12:271B5F6D-363D-11E5-9242-09173F13E4C5 n12:271B5F6E-363D-11E5-9242-09173F13E4C5 n12:271B5F67-363D-11E5-9242-09173F13E4C5 n12:271B5F68-363D-11E5-9242-09173F13E4C5 n12:271B5F65-363D-11E5-9242-09173F13E4C5 n12:271B5F66-363D-11E5-9242-09173F13E4C5 n12:271B5F6B-363D-11E5-9242-09173F13E4C5 n12:271B5F6C-363D-11E5-9242-09173F13E4C5 n12:271B5F69-363D-11E5-9242-09173F13E4C5 n12:271B5F6A-363D-11E5-9242-09173F13E4C5 n12:271B5F64-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination: Thought to be eliminated by non-renal mechanisms (i.e. hepatic metabolism, excretion in feces)
n3:synonym: N-(alpha-(Hydroxymethyl)ethyl)-D-lysergamide (6AR,9R)-7-methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide Ergonovine 9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8beta(S)-carboxamide Ergometrine N-(2-Hydroxy-1-methylethyl)-D(+)-lysergamide Ergobasine Ergotrate maleate 9,10-Didehydro-N-(alpha-(hydroxymethyl)ethyl)-6-methylergoline-8-beta-carboxamide Ergometrinum D-Lysergic acid 1-hydroxymethylethylamide Ergometrina [8beta(S)]-9,10-Didehydro-N-(2-hydroxy-1-methylethyl)-6-methylergoline-8-carboxamide D-Lysergic acid-L-propanolamide
n3:toxicity: The principal symptoms of overdose are convulsions and gangrene. Other symptoms include bradycardia, confusion, diarrhoea, dizziness, dyspnoea, drowsiness, fast and/or weak pulse, miosis, hypercoagulability, loss of consciousness, nausea and vomiting, numbness and coldness of the extremities, pain in the chest, peripheral vasoconstriction, respiratory depression, rise or fall in blood pressure, severe cramping of the uterus, tachycardia, tingling, and unusual thirst.
n5:hasAHFSCode: n7:76-00-00
n10:hasConcept: n11:M0007653
foaf:page: n14:ergonovine.html
n3:IUPAC-Name: n4:271B5F76-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B5F7C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B5F7B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B5F78-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B5F79-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B5F7A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B5F8C-363D-11E5-9242-09173F13E4C5 n4:271B5F74-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B5F8E-363D-11E5-9242-09173F13E4C5 n4:271B5F72-363D-11E5-9242-09173F13E4C5 n4:271B5F75-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B5F73-363D-11E5-9242-09173F13E4C5
n3:pKa: n4:271B5F8F-363D-11E5-9242-09173F13E4C5
n5:hasATCCode: n6:G02AB03
n3:H-Bond-Acceptor-Count: n4:271B5F82-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B5F83-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B5F7D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B5F7E-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B5F80-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B5F7F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B5F81-363D-11E5-9242-09173F13E4C5
n3:absorption: Absorption is rapid and complete after oral or intramuscular administration.
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 60-79-7
n3:category
n3:containedIn: n19:271B5F71-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n4:271B5F88-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B5F8A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B5F8B-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n4:271B5F8D-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B5F87-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B5F86-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B5F89-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B5F77-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n4:271B5F84-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B5F85-363D-11E5-9242-09173F13E4C5